Randomized double blind placebo controlled trial was done by Felicity cutts and colleagues in Gambia on the efficacy of a Nine Valent Pneumococcal Conjugate Vaccine (9-PCV) against radiologically confirmed pneumonia and invasive pneumococcal disesase in children immunized before 12 months of age.
The vaccine was found to reduce the incidence of vaccine type invasive pneumococcal disease by 77%, all serotype invasive Pneumococcal disease by 50%, all the hospital admissions by 15% and overall child mortality by 16%.
The 9-PCV trial reports the higher reduction in the incidence of radiological pneumonia than California and South African studies. The 9-PCV vaccines are used to help the fourth UN Millennium Development Goal in reducing the childhood mortality in developing countries. The evidence for efficacy of the vaccine in all hospital admissions is high.
Chest radiograph has shown high efficacy of the 9-PCV vaccines against pneumonia. The vaccine can also be used as an epidemiological tool to determine the amount of pneumonia due to Pneumococcus. Vaccine efficacy is detected by comparing the percentage reduction of disease incidence in a vaccinated group compared with an unvaccinated group.
In this study the scientists used WHO pneumonia case management algorithm for identifying clinical pneumonia and also WHO radiology standardized guidelines for reading chest radiographs. , Placebo, vaccine trial, nine valent pneumococcal conjugate vaccine, 9PCV, infection,
pneumonia, disease, children, serotype, trial report, chest radiograph, WHO.